A Phase 1b Study to Assess the Safety, Tolerability, and Efficacy of TAS-120 (Futibatinib) in Combination with MK-3475 (Pembrolizumab) in Patients with Solid Tumors (MK3475 - 990)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Nov 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Futibatinib (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Merck Sharp & Dohme Corp.; Taiho Pharmaceutical

13 Sep 2022 Results (n=30; as of 29 Nov 2021) from feasibility phase and expansion phase (cohort A and Cohort B) reporting safety and tolerability of futibatinib plus pembrolizumab in patients with advanced or metastatic solid tumors and first results for preliminary antitumor activity in patients with esophageal carcinoma presented at the 47th European Society for Medical Oncology Congress
05 Aug 2022 Planned number of patients changed from 133 to 273.
05 Aug 2022 Planned End Date changed from 30 Jun 2023 to 31 May 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com